Efficacy and Safety of Docetaxel plus Ramucirumab for Patients with Pretreated Advanced or Recurrent Non-small Cell Lung Cancer: Focus on Older Patients
ConclusionsThese findings suggest that the DTX + RAM combination is an effective second-line therapy for older patients with advanced or recurrent NSCLC, offering favorable efficacy without treatment discontinuation owing to adverse events.
Source: Targeted Oncology - Category: Cancer & Oncology Source Type: research
More News: Cancer | Cancer & Oncology | Chemotherapy | Docetaxel | Lung Cancer | Non-Small Cell Lung Cancer | Study | Taxotere